IMMP Immutep Quarterly EPS earnings growth

The quarterly EPS percentage change on GURU.Markets reflects dynamics amid a neutral geopolitical backdrop, with the parameter stabilizing at 3.50. Biotech company Immutep Limited (IMMP) is developing innovative LAG-3 therapy to combat solid tumors. Management is effectively expanding strategic collaboration with global pharma behemoths, confirming the uniqueness of its scientific research.

immutep.com (IMMP) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns and data insights for company Immutep Corp (IMMP)

- market value and analyst target forecast:

Price Chart Immutep|IMMP - Consensus Target

- market capitalization data:

Market Capitalization Immutep Limited ADR|IMMP - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Immutep|IMMP - Accounting Capitalization|Market Capitalization to Book Value Ratio immutep.com|IMMP - Company Total Asset Base

- company liabilities and liquidity data:

- earnings and market multiples details:

IMMP - Company Net Income|Expected Profit Immutep Limited|IMMP - Market Cap to Net Income|Projected Price to Earnings Immutep Limited ADR|IMMP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immutep Limited ADR|IMMP - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Immutep|IMMP - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months immutep.com|IMMP - Net earnings per share growth this year|Earnings growth forecast for next year Immutep Limited

Basic company analysis:Immutep, IMMP

For Immutep Limited (IMMP), this indicator serves as a tool to assess the scaling efficiency of its oncology pipeline. The calculation is based on the percentage change in net earnings per share between the current and previous quarters. By analyzing the growth rate of quarterly earnings per share, an investor determines the sustainability of the financial result. For the biotechnology sector, such price action confirms the success of clinical trials. Stable growth indicates the viability of the global expansion strategy.

Competitor analysis

Merus (MRUS) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Anixa Biosciences|ATOS (Atossa) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Context Tx CNTX|Year-over-year earnings per share growth for the last twelve months Mersana Therapeutics (MRSN)|briacell.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth EPIX (ESSA Pharma)|Year-over-year net earnings per share change for the last twelve months QT Imaging Holdings (QTI)